HCA’s Sarah Cannon Research Institute partners with Merck to expand access to oncology clinical trials in US communities

PUBT · 2d ago
HCA’s Sarah Cannon Research Institute partners with Merck to expand access to oncology clinical trials in US communities
  • HCA Healthcare’s Sarah Cannon Research Institute formed a strategic collaboration with Merck to expand access to oncology clinical trials.
  • Partnership will use SCRI’s Accelero model to streamline trial operations at community-based sites across the U.S.
  • Focus includes faster site activation, higher enrollment, fewer data changes, aiming to speed oncology drug development and broaden patient access.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCA Healthcare Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608130900BIZWIRE_USPR_____20260813_BW702734) on August 13, 2026, and is solely responsible for the information contained therein.